https://www.selleckchem.com/pr....oducts/tiragolumab-a
7%, 11% and 4.8% for the ≥70-year group (p=0.53. Median OS time, and 1,2,3-year OS rates were 14months, 54.1%, 23.4%, 13.9% for the 65-69-year old group, and 12months, 49.3%, 21.5%, 10% for the ≥70-year group (p=0.357). No differences were recorded in relation to different groups of age. The PSM analyses showed a similar outcome in 65-69-year old patients compared to older ones notwithstanding a more burdensome RT schedule. Hypofractionated RT treatment has to be considered also in this group of younger elderly, newly-d
Mi piace
Commento
Condividi
